Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 9/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25150433 | 0.95 | EPHX1 (0.67) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL19607946 | 0.93 | EPHX1 (0.70) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL12172818 | 0.91 | EPHX1 (0.71) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL1104746 | 0.86 | — | — | |
| SCHEMBL20317421 | 0.84 | EPHX1 (0.58) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL10812052 | 0.83 | EPHX1 (0.83) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL10817110 | 0.83 | EPHX1 (0.83) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL10812071 | 0.83 | EPHX1 (0.83) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL10817551 | 0.83 | EPHX1 (0.83) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL14067802 | 0.83 | EPHX1 (0.83) | EPHX1CHRNB2CHRNA4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021027566-A1 | PREPARATION METHOD FOR OXAZEPINE COMPOUND | 福建广生堂药业股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20200197409-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200197409-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | HAVCR2, CD74, HLA-B | EPHX1 1068/4885CHRNB2 3199/4885CHRNA4 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.